O. A. Soboleva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
O. A. Soboleva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Kirill R. Sabirov
National Medical Research Center for Hematology
4 shared publications - E. A. Kitsenko
Russian Scientific Center of Surgery named after academician B.V. Petrovsky
3 shared publications - Karen I. Danishian
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
3 shared publications - Anait Levonovna Melikyan
National Medical Research Center for Hematology
2 shared publications - A. N. Bashkov
State Research Center – Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
1 shared publication - A. V. Kovalenko
National Medical Research Center for Hematology
1 shared publication
Latest Publications
- 30 June 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (3)
Acute Simultaneous Thrombosis of the Hepatic Veins and the Portal System in a 30-Year-Old Female with JAK2-Positive Essential Thrombocythemia
Aim: to present a clinical case of simultaneous thrombosis of the hepatic veins and total thrombosis of the vessels of the portal system in a myeloproliferative neoplasm. Key points. The patient was admitted to the gastroenterology department with complaints of abdominal distension, abdominal pain syndrome, and hyperthermia. An examination revealed widespread thrombosis of the hepatic veins and the portal system. Conservative therapy with diuretics, low-molecular-weight heparins, and albumin preparations proved ineffective. The patient was referred to a federal clinic for verification of the diagnosis of myeloproliferative neoplasm. As a result of the examination, a diagnosis of essential thrombocythemia was established. Against the background of comprehensive conservative therapy, a regression of refractory ascites was achieved. The patient is under dynamic observation of a hematologist, a hepatologist, hepatobiliary surgeon, and a transplantologist.
- 30 June 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (3)
Acute Simultaneous Thrombosis of the Hepatic Veins and the Portal System in a 30-Year-Old Female with JAK2-Positive Essential Thrombocythemia
Aim: to present a clinical case of simultaneous thrombosis of the hepatic veins and total thrombosis of the vessels of the portal system in a myeloproliferative neoplasm. Key points. The patient was admitted to the gastroenterology department with complaints of abdominal distension, abdominal pain syndrome, and hyperthermia. An examination revealed widespread thrombosis of the hepatic veins and the portal system. Conservative therapy with diuretics, low-molecular-weight heparins, and albumin preparations proved ineffective. The patient was referred to a federal clinic for verification of the diagnosis of myeloproliferative neoplasm. As a result of the examination, a diagnosis of essential thrombocythemia was established. Against the background of comprehensive conservative therapy, a regression of refractory ascites was achieved. The patient is under dynamic observation of a hematologist, a hepatologist, hepatobiliary surgeon, and a transplantologist.
- Open Access
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 163-170
Esophagogastric Bleedings in Patients with Ph-Negative Myeloproliferative Neoplasms and Extrahepatic Portal Hypertension
AIM. To assess the treatment outcomes in esophagogastric bleeding patients with Ph-negative myeloproliferative neoplasms (MPN) and extrahepatic portal hypertension caused by thrombotic complications. MATERIALS & METHODS. The present prospective clinical trial performed in the surgical department of the National Research Center for Hematology from 2013 to 2024 enrolled 52 patients with Ph-negative MPNs and extrahepatic portal hypertension caused by total portal vein thrombosis. The median age of patients was 45 years (range 25–68 years). Young (≤ 40 years) and middle-aged (≤ 60 years) patients predominated: 16 (30.8 %) and 31 (59.6 %), respectively. There were 5 (9.6 %) elderly (> 60 years) patients. The V617F mutation in JAK2 was detected in 41 (78.8 %) out of 52 patients. RESULTS. Splenectomy was performed in 49 patients, 41 (78.8 %) out of them also underwent gastrotomy as well as esophageal/gastric variceal ligation. Gastrotomy was not carried out in 10 (19.2 %) out of 52 patients. Laparotomy with gastrotomy along with esophageal and gastric variceal ligation (without splenectomy) was performed in 3 (5.8 %) patients. Repeated bleedings were registered in 2 of them, which required further splenectomy. Overall incidence of postoperative complications was 21 %. Long-term rebleedings reported in 7 (13.5 %) patients were treated non-surgically. The 5-year overall survival in the total group (n = 52) was 90.1 %. At later stages of Ph-negative MPNs, 5 (9.6 %) deaths were registered as a result of the blast transformation of the disease (n = 3) and thrombohemorrhagic complications (n = 2). CONCLUSION. Patients with Ph-negative MPNs and extrahepatic portal hypertension caused by portal vein thrombosis represent most complicated cases. However, surgical procedures, such as splenectomy combined with gastrotomy and esophageal/gastric variceal ligation, considerably improve long-term treatment outcomes despite a relatively high incidence of postoperative complications (thrombotic, hemorrhagic, purulent, and inflammatory ones).
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 163-170
Open AccessEsophagogastric Bleedings in Patients with Ph-Negative Myeloproliferative Neoplasms and Extrahepatic Portal Hypertension
AIM. To assess the treatment outcomes in esophagogastric bleeding patients with Ph-negative myeloproliferative neoplasms (MPN) and extrahepatic portal hypertension caused by thrombotic complications. MATERIALS & METHODS. The present prospective clinical trial performed in the surgical department of the National Research Center for Hematology from 2013 to 2024 enrolled 52 patients with Ph-negative MPNs and extrahepatic portal hypertension caused by total portal vein thrombosis. The median age of patients was 45 years (range 25–68 years). Young (≤ 40 years) and middle-aged (≤ 60 years) patients predominated: 16 (30.8 %) and 31 (59.6 %), respectively. There were 5 (9.6 %) elderly (> 60 years) patients. The V617F mutation in JAK2 was detected in 41 (78.8 %) out of 52 patients. RESULTS. Splenectomy was performed in 49 patients, 41 (78.8 %) out of them also underwent gastrotomy as well as esophageal/gastric variceal ligation. Gastrotomy was not carried out in 10 (19.2 %) out of 52 patients. Laparotomy with gastrotomy along with esophageal and gastric variceal ligation (without splenectomy) was performed in 3 (5.8 %) patients. Repeated bleedings were registered in 2 of them, which required further splenectomy. Overall incidence of postoperative complications was 21 %. Long-term rebleedings reported in 7 (13.5 %) patients were treated non-surgically. The 5-year overall survival in the total group (n = 52) was 90.1 %. At later stages of Ph-negative MPNs, 5 (9.6 %) deaths were registered as a result of the blast transformation of the disease (n = 3) and thrombohemorrhagic complications (n = 2). CONCLUSION. Patients with Ph-negative MPNs and extrahepatic portal hypertension caused by portal vein thrombosis represent most complicated cases. However, surgical procedures, such as splenectomy combined with gastrotomy and esophageal/gastric variceal ligation, considerably improve long-term treatment outcomes despite a relatively high incidence of postoperative complications (thrombotic, hemorrhagic, purulent, and inflammatory ones).
- 20 March 2025
- Published by Media Sphere Publishing Group in Endoscopic Surgery
- Vol. 31 (2)
Perioperative complications of splenectomy in hematological patients
Objective. To present the current stock of knowledge about perioperative complications of splenectomy for hematological disorders. Key issues. The use of minimally invasive technologies in hematological surgery has reduced the incidence of intra- and postoperative complications. However, both laparoscopic and open splenectomy are associated with technical difficulties in patients with blood diseases. Splenectomy is significantly complicated by severe splenomegaly, perisplenitis, portal hypertension, hemostatic disorders, severity of the hematological disease and the initial somatic condition of patients. Regardless of the selected approach, surgical (bleeding, pancreatic tail injury, pancreatic fistula, subdiaphragmatic abscess, etc.) and non-surgical (infections, portal system thrombosis) complications may develop in the perioperative period. Conclusion. Topographic and anatomical characteristics of the spleen, experience of the surgical team, as well as general condition of patients and the course of underlying disease and treatment modality play critical role in the development of perioperative complications.
- 20 March 2025
- Published by Media Sphere Publishing Group in Endoscopic Surgery
- Vol. 31 (2)
Perioperative complications of splenectomy in hematological patients
Objective. To present the current stock of knowledge about perioperative complications of splenectomy for hematological disorders. Key issues. The use of minimally invasive technologies in hematological surgery has reduced the incidence of intra- and postoperative complications. However, both laparoscopic and open splenectomy are associated with technical difficulties in patients with blood diseases. Splenectomy is significantly complicated by severe splenomegaly, perisplenitis, portal hypertension, hemostatic disorders, severity of the hematological disease and the initial somatic condition of patients. Regardless of the selected approach, surgical (bleeding, pancreatic tail injury, pancreatic fistula, subdiaphragmatic abscess, etc.) and non-surgical (infections, portal system thrombosis) complications may develop in the perioperative period. Conclusion. Topographic and anatomical characteristics of the spleen, experience of the surgical team, as well as general condition of patients and the course of underlying disease and treatment modality play critical role in the development of perioperative complications.
- Open Access
- 27 February 2024
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 23 (1) , 117-128
Diagnostics and treatment of complicated perianal abscess in patients with hematologic malignancies
Диагностика и лечение сложных форм острого парапроктита у пациентов с опухолевыми заболеваниями системы крови
- 27 February 2024
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 23 (1) , 117-128
Open AccessDiagnostics and treatment of complicated perianal abscess in patients with hematologic malignancies
Диагностика и лечение сложных форм острого парапроктита у пациентов с опухолевыми заболеваниями системы крови
- Open Access
- 7 July 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (2) , 282-294-294
Treatment tactics for a patient with acquired hemophilia: continuous infusion of recombinant activated coagulation factor VII and the inhibitor eradication
Introduction. Acquired hemophilia is a rare autoimmune disease caused by an inhibitor to clotting factor VIII (FVIII). It complicates the course of many diseases, in particular autoimmune diseases, and in women is often associated with pregnancy.Aim — to present a case of successful treatment of a patient with acquired hemophilia using long-term continuous infusion of rFVIIa and inhibitor eradication as a result of immunosuppressive therapy.Main findings. A clinical observation of severe hemorrhagic syndrome in a patient with acquired hemophilia associated with pregnancy is presented. Uterine bleeding in the patient after spontaneous delivery, refractory to standard hemorrhagic syndrome treatment, required multiple surgical interventions. Laboratory tests showed prolongation of APTT, CT in the INTEM rotational thromboelastometry test, a decrease in plasma FVIII activity and presence of inhibitor to FVIII. Vacuum-assisted closure was applied to treat infected laparotomy wound. Therapy for acquired hemophilia consisted of hemostatic therapy and the inhibitor eradication. Hemostatic therapy included a continuous infusion of rFVIIa at a rate of 30 μg/kg/h with a gradual decrease up to 9.6 μg/kg/h, as well as its fractional administration before every surgery at a dosage of 80 μg/kg. The effectiveness of the therapy was assessed by the dynamics of CT in the INTEM test and the shortening of the APTT. The inhibitor eradication was achieved by prednisolone therapy, combined immunosuppression with rituximab and azathioprine, followed by its replacement with cyclophosphamide. As a result, the hemorrhage was stopped, reference plasma activity of FVIII and eradication of the inhibitor were reached.
- 7 July 2022
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 67 (2) , 282-294-294
Open AccessTreatment tactics for a patient with acquired hemophilia: continuous infusion of recombinant activated coagulation factor VII and the inhibitor eradication
Introduction. Acquired hemophilia is a rare autoimmune disease caused by an inhibitor to clotting factor VIII (FVIII). It complicates the course of many diseases, in particular autoimmune diseases, and in women is often associated with pregnancy.Aim — to present a case of successful treatment of a patient with acquired hemophilia using long-term continuous infusion of rFVIIa and inhibitor eradication as a result of immunosuppressive therapy.Main findings. A clinical observation of severe hemorrhagic syndrome in a patient with acquired hemophilia associated with pregnancy is presented. Uterine bleeding in the patient after spontaneous delivery, refractory to standard hemorrhagic syndrome treatment, required multiple surgical interventions. Laboratory tests showed prolongation of APTT, CT in the INTEM rotational thromboelastometry test, a decrease in plasma FVIII activity and presence of inhibitor to FVIII. Vacuum-assisted closure was applied to treat infected laparotomy wound. Therapy for acquired hemophilia consisted of hemostatic therapy and the inhibitor eradication. Hemostatic therapy included a continuous infusion of rFVIIa at a rate of 30 μg/kg/h with a gradual decrease up to 9.6 μg/kg/h, as well as its fractional administration before every surgery at a dosage of 80 μg/kg. The effectiveness of the therapy was assessed by the dynamics of CT in the INTEM test and the shortening of the APTT. The inhibitor eradication was achieved by prednisolone therapy, combined immunosuppression with rituximab and azathioprine, followed by its replacement with cyclophosphamide. As a result, the hemorrhage was stopped, reference plasma activity of FVIII and eradication of the inhibitor were reached.
- Open Access
- 25 October 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (3) , 362-373-373
Effi cacy of splenectomy in primary immune thrombocytopenia
Introduction. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. Splenectomy is one the most effective treatment methods for this disorder.Aim — to evaluate the effi cacy and safety of a splenectomy in patients with primary immune thrombocytopenia.Subjects and methods. 111 patients (31 males, 80 females) with primary immune thrombocytopenia who were hospitalized to perform laparoscopic splenectomy were included in a prospective study conducted at the National Research Center for Hematology from 2015 to 2019. Disease duration from onset to splenectomy was from 1 month to 51 years. Response to the splenectomy, complications, and correlation with immediate preoperative platelet count were analyzed.Results. Complete response was achieved in 79 (71.2 %) cases, a partial response was achieved in 11 (9.9 %) cases, and in 21 (18.9 %) cases there was no response. Immediate preoperative platelet count was signifi cantly higher in patients with complete response in comparison with the group with no response, median (95% CI): 47 (35–58) vs 16 (9–20), p < 0.001.Multivariate analysis (logistic regression) was performed. According to this regression, a risk factor for an unfavorable response was detected — males > 60 years of age, p = 0.05; RR (95% CI): 2.0 (0.9–7.1). A predictor of unfavorable response was identifi ed – immediate preoperative platelet count < 23 × 109/l (cutoff point determined in ROC-analysis); p = 0.001, RR (95% CI): 2.5 (1.1–8.6). The probability of complete response was lower with the number of treatment lines prior to splenectomy (weak inverse correlation: r S = −0.30; p = 0.01). The frequency of postoperative complications was 12.6 %. According to our follow-up data, a complete response was preserved in 66/79 (83.5 %) of patients, with a follow-up of 2.7 years.Conclusion. Splenectomy is an effective and safe treatment method for ITP. Factors of unfavorable response were identifi ed: males > 60 years of age and immediate preoperative platelet count < 23 × 109/l. It is safe to perform splenectomy regardless of effectiveness of preoperative splenectomy treatment and platelet count.
- 25 October 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (3) , 362-373-373
Open AccessEffi cacy of splenectomy in primary immune thrombocytopenia
Introduction. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. Splenectomy is one the most effective treatment methods for this disorder.Aim — to evaluate the effi cacy and safety of a splenectomy in patients with primary immune thrombocytopenia.Subjects and methods. 111 patients (31 males, 80 females) with primary immune thrombocytopenia who were hospitalized to perform laparoscopic splenectomy were included in a prospective study conducted at the National Research Center for Hematology from 2015 to 2019. Disease duration from onset to splenectomy was from 1 month to 51 years. Response to the splenectomy, complications, and correlation with immediate preoperative platelet count were analyzed.Results. Complete response was achieved in 79 (71.2 %) cases, a partial response was achieved in 11 (9.9 %) cases, and in 21 (18.9 %) cases there was no response. Immediate preoperative platelet count was signifi cantly higher in patients with complete response in comparison with the group with no response, median (95% CI): 47 (35–58) vs 16 (9–20), p < 0.001.Multivariate analysis (logistic regression) was performed. According to this regression, a risk factor for an unfavorable response was detected — males > 60 years of age, p = 0.05; RR (95% CI): 2.0 (0.9–7.1). A predictor of unfavorable response was identifi ed – immediate preoperative platelet count < 23 × 109/l (cutoff point determined in ROC-analysis); p = 0.001, RR (95% CI): 2.5 (1.1–8.6). The probability of complete response was lower with the number of treatment lines prior to splenectomy (weak inverse correlation: r S = −0.30; p = 0.01). The frequency of postoperative complications was 12.6 %. According to our follow-up data, a complete response was preserved in 66/79 (83.5 %) of patients, with a follow-up of 2.7 years.Conclusion. Splenectomy is an effective and safe treatment method for ITP. Factors of unfavorable response were identifi ed: males > 60 years of age and immediate preoperative platelet count < 23 × 109/l. It is safe to perform splenectomy regardless of effectiveness of preoperative splenectomy treatment and platelet count.